Valerie Odegard
Independent DirectorDr. Valerie Odegard, Ph.D., is Venture Partner of OrbiMed Advisors LLC. Dr. Odegard was Director of Abata Therapeutics, Inc. from July 2021 until 2025. Dr. Odegard has served as the Chief Executive Officer of Dovetail Therapeutics, Inc. since October 2023. Dr. Odegard is an Independent Director of Odyssey Therapeutics, Inc. sine October 2021. Dr. Odegard was President & Chief Scientific Officer of Silverback Therapeutics, Inc. from September 2020 to September 02, 2022. Dr. Odegard was employed at Silverback Therapeutics, Inc. from 2016 to September 02, 2022. She served as President & Chief Scientific Officer of ARS Pharmaceuticals, Inc. Dr. Odegard was Member of Scientific Advisory Board of iTeos Therapeutics, Inc. until 2022. Dr. Odegard was employed at iTeos Therapeutics, Inc. until 2022. Previously, Dr. Odegard served as Vice President of Research at Juno Therapeutics, where she was responsible for the discovery and development of novel immunotherapies for cancer. Prior to Juno, she held research leadership positions at Novo Nordisk and Trubion, where she was responsible for the advancement of therapeutics for oncology and inflammatory conditions. Dr. Odegard has B.S. in Biology from Wake Forest University, Ph.D. in Immunobiology from Yale University.
Positions
- Company NameOdyssey Therapeutics, Inc.Stock CodeODTXPositionIndependent DirectorColleagues
- GDGary D. GlickFounder, President, CEO & Director
- JMJeffrey Marc LeidenIndependent Chairman of the Board
- JHJason HaasChief Financial Officer
- CTCollin ToddSenior Vice President of Strategy & Business Development
- ELEicke LatzScientific Co-Founder
- KLKim LewisScientific Co-Founder
- SCStephen C. BlacklowChairman of Scientific Advisory Board
- IFIan F. SmithIndependent Director
